Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05122494
Other study ID # HM022BC3C01
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date January 19, 2022
Est. completion date June 2024

Study information

Verified date July 2022
Source Tianjin Hemay Oncology Pharmaceutical Co., Ltd
Contact Huiping Li
Phone 13811012595
Email huipingli2012@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase III, randomized, multicenter, 2-arm, open-label clinical trial designed to compare the safety and efficacy of Hemay022+Aromatase inhibitor(AI) with that of capecitabine + lapatinib in participants with ER+/HER2+ locally advanced or metastatic breast cancer. Participants will be treated until disease progression (PD), unmanageable toxicity, or study termination. Once disease progression is reported, all participants will be followed for survival every 3 months until death, loss to follow-up.


Recruitment information / eligibility

Status Recruiting
Enrollment 339
Est. completion date June 2024
Est. primary completion date February 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age =18 years old; 2. Subjects must give informed consent to the study before the study entry and voluntarily sign a written informed consent form; 3. Breast cancer subjects diagnosed by pathology; 4. ER positive and HER2 over-expression; 5. Advanced/metastatic breast cancer that has previously received treatment failure with trastuzumab (or trastuzumab biosimilar) regimen; 6. Measurable and/or nonmeasurable disease; 7. (Eastern Cooperative Oncology Group)ECOG Performance Status of 0-1; 8. The estimated survival time is more than 3 months; 9. Postmenopausal women; 10. Adequate bone marrow, liver, kidney, and coagulation Bone Marrow Function; 11. All previous treatment-related toxicities must be Common Terminology Criteria of Adverse Events (CTCAE ,version 5.0) = Grade 2 at the time of randomization, except for hair loss, pigmentation, and long-term toxicity caused by radiotherapy (which cannot be recovered by the investigator's judgment); 12. Women patients of childbearing age (including their partners) have no pregnancy plan and voluntarily take effective contraceptive measures from the signing of the informed consent form to 3 months after the last medication. Exclusion Criteria: 1. Patients with visceral crisis; 2. Patients with the presence of spinal cord compression or brain, meningeal metastases; 3. Patients who have been treated with a small molecule HER2 tyrosine kinase inhibitor (HER2-TKI) (medication course =2 weeks is excluded) 4. Have received radiotherapy within 4 weeks prior to study; 5. Have received chemotherapy for advanced breast cancer> 1 lines ; 6. Patients with parenteral nutrition; malabsorption syndrome; or any condition possibly affecting drug absorption or inability to tolerate oral medications; 7. Use of any drug that inhibits or induces hepatic metabolism of Hemay022 within 2 weeks prior to study and entire study duration; 8. Patients who are known to have a history of allergies to Hemay022, lapatinib?AI (letrozole, exemestane) capecitabine or similar drugs; 9. Left ventricular ejection fraction (LVEF) <50%; 10. Positive blood for human immunodeficiency virus (HIV antibody); Positive hepatitis B surface antigen and HBV-DNA>upper limit of normal; Active hepatitis C virus (HCV) infection 11. Patients with active infection requiring intravenous anti-infective treatment 12. Arrhythmias requiring treatment ; 13. Confirmed QTc prolongation (=500ms) ; 14. People with a history of interstitial lung disease that needs treatment, a history of radiation pneumonitis, or clinically active interstitial lung disease 15. Have received other clinical trial drugs within 4 weeks before the study 16. Major surgery or injury less than 4 weeks before the study 17. The study period must be accompanied by other antitumor therapy,such as chemotherapy, targeted therapy, hormone therapy, immunotherapy, radiotherapy (except symptomatic local radiotherapy) 18. Any other malignant cancer within 5 years with the exception of adequately treated cervical cancer in situ or basal and squamous cutaneous cell carcinomas 19. Any condition that would make the subject inappropriate for this study by the investigator's judgment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Hemay022+AI
hemay022:orally once daily,A 21-day cycle
Lapatinib+Capecitabine
Take the pills according to the instructions

Locations

Country Name City State
China Beijing Cancer Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Tianjin Hemay Oncology Pharmaceutical Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Median progression-free survival(mPFS)based on Independent Review Committee (IRC) assessment according to RECIST v1.1 PFS defined as the proportion of patients alive and without progression From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 month
Secondary Overall Survival (OS) of the two group according to RECIST v1.1 OS is defined as the time from random to any cause of death From date of randomization until the date of death from any cause, whichever came first,assessed up to 36 months
Secondary Objective response rate ( ORR, partial response rate+ complete response rate) according to RECIST v1.1 ORR defined as the proportion of subjects in complete response (CR) or (partial response) PR From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 month
Secondary Clinical benefit rate (CBR) according to RECIST v1.1 Clinical benefit rate defined as percentage of patients with stable disease (SD) = 6 months/partial response (PR)/complete response (CR) From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 month
Secondary Duration of Response (DOR) according to RECIST v1.1 DOR defined as the duration after the first assessment as CR or PR, only applicable to subjects who have achieved remission From the first recorded CR or PR until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 month
Secondary Time to Response (TTR) TTR defined as the time from random to CR or PR for the first time From date of randomization until the date of the first recorded CR or PR assessed up to 36 month
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Recruiting NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A